We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Strength Seen in Humana (HUM): Can Its 11.6% Jump Turn into More Strength?
Read MoreHide Full Article
Humana (HUM - Free Report) shares soared 11.6% in the last trading session to close at $431.87. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 3.4% loss over the past four weeks.
Humana stock witnessed a price rise, driven by strength in its Medicare footprint. As of June 30, 2026, the company served 17.9 million medical members, up 20.7% year over year. Individual Medicare Advantage membership increased 23.4% to 6.5 million, while total Medicare membership rose 35.3% to 11.1 million. Its broad membership base, extensive provider networks and longstanding Medicare expertise support market penetration and care coordination capabilities.
Humana's CenterWell platform further strengthens its competitive position by integrating pharmacy, primary care and home health services. During the first half of 2026, CenterWell's external revenues rose 32.2% to $3 billion, supported by 65.7% growth in primary care revenues to $1.6 billion. The company's value-based care model covered approximately 4.1 million individual Medicare Advantage members at June 30, 2026, supporting coordinated care, improved patient outcomes and medical cost management.
This health insurer is expected to post quarterly loss of $1.04 per share in its upcoming report, which represents a year-over-year change of -132.1%. Revenues are expected to be $40.46 billion, up 23.9% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Humana, the consensus EPS estimate for the quarter has been revised 2.7% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on HUM going forward to see if this recent jump can turn into more strength down the road.
Humana belongs to the Zacks Medical - HMOs industry. Another stock from the same industry, The Joint Corp. (JYNT - Free Report) , closed the last trading session 1.1% lower at $7.04. Over the past month, JYNT has returned -11.3%.
For The Joint, the consensus EPS estimate for the upcoming report has changed +9.1% over the past month to $0.11. This represents a change of +450% from what the company reported a year ago. The Joint currently has a Zacks Rank of #3 (Hold).
View the Zacks #1 Rank List
Image: Bigstock
Strength Seen in Humana (HUM): Can Its 11.6% Jump Turn into More Strength?
Humana (HUM - Free Report) shares soared 11.6% in the last trading session to close at $431.87. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 3.4% loss over the past four weeks.
Humana stock witnessed a price rise, driven by strength in its Medicare footprint. As of June 30, 2026, the company served 17.9 million medical members, up 20.7% year over year. Individual Medicare Advantage membership increased 23.4% to 6.5 million, while total Medicare membership rose 35.3% to 11.1 million. Its broad membership base, extensive provider networks and longstanding Medicare expertise support market penetration and care coordination capabilities.
Humana's CenterWell platform further strengthens its competitive position by integrating pharmacy, primary care and home health services. During the first half of 2026, CenterWell's external revenues rose 32.2% to $3 billion, supported by 65.7% growth in primary care revenues to $1.6 billion. The company's value-based care model covered approximately 4.1 million individual Medicare Advantage members at June 30, 2026, supporting coordinated care, improved patient outcomes and medical cost management.
This health insurer is expected to post quarterly loss of $1.04 per share in its upcoming report, which represents a year-over-year change of -132.1%. Revenues are expected to be $40.46 billion, up 23.9% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Humana, the consensus EPS estimate for the quarter has been revised 2.7% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on HUM going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Humana belongs to the Zacks Medical - HMOs industry. Another stock from the same industry, The Joint Corp. (JYNT - Free Report) , closed the last trading session 1.1% lower at $7.04. Over the past month, JYNT has returned -11.3%.
For The Joint, the consensus EPS estimate for the upcoming report has changed +9.1% over the past month to $0.11. This represents a change of +450% from what the company reported a year ago. The Joint currently has a Zacks Rank of #3 (Hold).